In formulating either a positive or negative view of global healthcare businesses, one has to consider the US healthcare system being the largest in the world in terms of both drug and medical device sales.
It spends far more as a percentage of GDP than any other developed nation at over 16%, and accounts for roughly 40% (or $425bn) of global pharmaceuticals sales and about 44% (or $190bn) of global medical device sales. It is no surprise that all the companies we invest in within the healthcare sector have significant exposure to the US market. Long-term investors should focus on the positive fundamentals driving long-term earnings growth within the healthcare industry. Four unloved healthcare stocks that stand to benefit from ageing populations Exposure should clearly not just b...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
